Omer Anis, Saar Anis, Myles M Reed, Daniel Teixeira-Dos-Santos, Shelley Ivary, Tyler Trump, Howard B Goldman
{"title":"Urologic Symptom Management in Parkinson's Disease - Current Treatments and Emerging Directions - Systematic Review.","authors":"Omer Anis, Saar Anis, Myles M Reed, Daniel Teixeira-Dos-Santos, Shelley Ivary, Tyler Trump, Howard B Goldman","doi":"10.1007/s11934-025-01297-x","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose of review: </strong>This review synthesizes current evidence on therapeutic strategies for Parkinson's disease (PD)-related overactive bladder (OAB), encompassing PD-targeted treatments, pharmacologic interventions, and advanced therapies such as neuromodulation and intravesical botulinum toxin. We address the complexity of managing lower urinary tract symptoms (LUTS) in patients with PD due to progressive neurodegeneration affecting micturition control and cognitive vulnerabilities in this population.</p><p><strong>Recent findings: </strong>A thorough review of available literature shows that chronic levodopa improves bladder capacity and reduces urgency, though acute dosing may worsen symptoms in advanced stages. Subthalamic nucleus-deep brain stimulation enhances bladder function and symptom scores, possibly by modulating basal ganglia-thalamocortical circuits. Anticholinergics are effective but pose cognitive risks, warranting careful use guided by anticholinergic burden assessments. In contrast, beta-3 agonists such as mirabegron offer a safer cognitive profile with emerging efficacy data. Finally, intravesical botulinum toxin and neuromodulation present promising third-line options, though data in PD remain limited, and larger trials are still needed to confirm their role. Optimal management of LUTS in PD requires individualized, stage-specific, multidisciplinary strategies balancing efficacy and cognitive safety. Further high-quality, disease-specific studies are essential to develop tailored treatment algorithms and improve quality of life in this growing patient population.</p>","PeriodicalId":11112,"journal":{"name":"Current Urology Reports","volume":"26 1","pages":"77"},"PeriodicalIF":3.2000,"publicationDate":"2025-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Urology Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11934-025-01297-x","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose of review: This review synthesizes current evidence on therapeutic strategies for Parkinson's disease (PD)-related overactive bladder (OAB), encompassing PD-targeted treatments, pharmacologic interventions, and advanced therapies such as neuromodulation and intravesical botulinum toxin. We address the complexity of managing lower urinary tract symptoms (LUTS) in patients with PD due to progressive neurodegeneration affecting micturition control and cognitive vulnerabilities in this population.
Recent findings: A thorough review of available literature shows that chronic levodopa improves bladder capacity and reduces urgency, though acute dosing may worsen symptoms in advanced stages. Subthalamic nucleus-deep brain stimulation enhances bladder function and symptom scores, possibly by modulating basal ganglia-thalamocortical circuits. Anticholinergics are effective but pose cognitive risks, warranting careful use guided by anticholinergic burden assessments. In contrast, beta-3 agonists such as mirabegron offer a safer cognitive profile with emerging efficacy data. Finally, intravesical botulinum toxin and neuromodulation present promising third-line options, though data in PD remain limited, and larger trials are still needed to confirm their role. Optimal management of LUTS in PD requires individualized, stage-specific, multidisciplinary strategies balancing efficacy and cognitive safety. Further high-quality, disease-specific studies are essential to develop tailored treatment algorithms and improve quality of life in this growing patient population.
期刊介绍：
This journal intends to review the most important, recently published findings in the field of urology. By providing clear, insightful, balanced contributions by international experts, the journal elucidates current and emerging approaches to the care and prevention of urologic diseases and conditions.
We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as benign prostatic hyperplasia, erectile dysfunction, female urology, and kidney disease. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
